Corbus Pharmaceuticals Holding
Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation o… Read more
Market Cap & Net Worth: Corbus Pharmaceuticals Holding (CRBP)
Corbus Pharmaceuticals Holding (NASDAQ:CRBP) has a market capitalization of $169.04 Million ($169.04 Million) as of March 18, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #17552 globally and #6644 in its home market, demonstrating a 0.84% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Corbus Pharmaceuticals Holding's stock price $9.63 by its total outstanding shares 17553037 (17.55 Million).
Corbus Pharmaceuticals Holding Market Cap History: 2015 to 2026
Corbus Pharmaceuticals Holding's market capitalization history from 2015 to 2026. Data shows change from $868.88 Million to $169.04 Million (-15.07% CAGR).
Index Memberships
Corbus Pharmaceuticals Holding is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.24 Trillion | 0.01% | #479 of 976 |
|
NASDAQ Composite
IXIC
|
$33.39 Trillion | 0.00% | #1636 of 3165 |
Weight: Corbus Pharmaceuticals Holding's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Corbus Pharmaceuticals Holding Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Corbus Pharmaceuticals Holding's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
367.72x
Corbus Pharmaceuticals Holding's market cap is 367.72 times its annual revenue
1728.56x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $868.88 Million | $648.38K | -$8.85 Million | 1340.07x | N/A |
| 2016 | $4.45 Billion | $1.91 Million | -$20.00 Million | 2327.95x | N/A |
| 2017 | $3.74 Billion | $2.44 Million | -$32.42 Million | 1532.17x | N/A |
| 2018 | $3.08 Billion | $4.82 Million | -$55.67 Million | 637.73x | N/A |
| 2019 | $2.88 Billion | $36.14 Million | -$71.45 Million | 79.55x | N/A |
| 2020 | $658.24 Million | $3.94 Million | -$111.27 Million | 167.18x | N/A |
| 2021 | $324.22 Million | $881.71K | -$45.55 Million | 367.72x | N/A |
Competitor Companies of CRBP by Market Capitalization
Companies near Corbus Pharmaceuticals Holding in the global market cap rankings as of March 18, 2026.
Key companies related to Corbus Pharmaceuticals Holding by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
Corbus Pharmaceuticals Holding Historical Marketcap From 2015 to 2026
Between 2015 and today, Corbus Pharmaceuticals Holding's market cap moved from $868.88 Million to $ 169.04 Million, with a yearly change of -15.07%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $169.04 Million | +18.30% |
| 2025 | $142.88 Million | -31.02% |
| 2024 | $207.13 Million | +95.36% |
| 2023 | $106.02 Million | +82.20% |
| 2022 | $58.19 Million | -82.05% |
| 2021 | $324.22 Million | -50.74% |
| 2020 | $658.24 Million | -77.11% |
| 2019 | $2.88 Billion | -6.51% |
| 2018 | $3.08 Billion | -17.75% |
| 2017 | $3.74 Billion | -15.98% |
| 2016 | $4.45 Billion | +412.12% |
| 2015 | $868.88 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Corbus Pharmaceuticals Holding was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $169.04 Million USD |
| MoneyControl | $169.04 Million USD |
| MarketWatch | $169.04 Million USD |
| marketcap.company | $169.04 Million USD |
| Reuters | $169.04 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.